VLTS 934
Alternative Names: PINC polymer; PoloxamerLatest Information Update: 15 Dec 2021
Price :
$50 *
At a glance
- Originator Valentis
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Peripheral arterial occlusive disorders
Most Recent Events
- 14 Jul 2006 Results from a phase IIb clinical trial in patients with intermittent claudication have been added to the adverse events and Vascular Disorders therapeutic trials sections
- 11 Jul 2006 Discontinued - Phase-II for Peripheral arterial occlusive disorders in USA (unspecified route)
- 16 Feb 2006 Valentis has completed enrolment in the phase IIb trial for Peripheral arterial disease in the US